Search

everythinglearnresearchcommunity

for

Search:↓

Frontal Fibrosing Alopecia might be an autoimmune disease.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Testosterone treatment can improve sexual function and bone density in women but may have adverse effects and requires more research on safety and guidelines.

Frontal fibrosing alopecia can occur in children, not just postmenopausal women.

Frontal fibrosing alopecia causes hair loss along the frontal hairline, mainly in postmenopausal women, and needs better treatments.

Frontal fibrosing alopecia in men is often misdiagnosed and needs better diagnostic criteria and treatments.

The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.

No treatment has been proven to effectively stop hair loss or regrow hair in Frontal Fibrosing Alopecia, and more research is needed.

The study concludes that early diagnosis of Frontal Fibrosing Alopecia is important, as it is often found in postmenopausal women, may be related to Lichen Planopilaris, and eyebrow hair loss is a common sign.

The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.

High testosterone increases heart disease risk in women with PCOS.

Familial frontal fibrosing alopecia affects premenopausal women too, and early diagnosis is important, but no proven medication exists yet.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

A new diagnostic tool for Vulvovaginal Lichen Planus is highly accurate, and updated treatments for various skin conditions, including melanoma and Hidradenitis Suppurativa, were discussed.

Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.

Hair and nail conditions can stabilize or improve over time, and new treatments show promise.

Eating a balanced diet with specific nutrients can help manage menopause symptoms and prevent related health issues.

Male hormones, particularly DHT, are linked to male pattern hair loss, and treatments like finasteride can help, but they don't work for postmenopausal women's hair loss, which may have different causes.

Vitamin D and estrogen may help protect heart and kidney health, and maintaining sufficient vitamin D levels could be especially beneficial for African Americans, postmenopausal women, and people with chronic kidney disease.

Testosterone implants in women require pharmacological dosing to be effective and are generally safe and well-tolerated.

Certain microRNAs might help identify and understand Frontal Fibrosing Alopecia.

Familial frontal fibrosing alopecia is rare, mostly affects women, and often occurs between sisters or mother-daughter pairs.

Over-the-counter products can help with menopause symptoms, but be aware of their ingredients.

Testosterone therapy can improve sexual satisfaction and mood in surgically menopausal women when used with estrogen, but its long-term safety and effects on naturally menopausal and premenopausal women are unclear.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Dihydrotestosterone and 5α-Reductase play a role in hair loss and prostate health, and finasteride can increase hair growth in men without affecting sperm production, but it doesn't work for postmenopausal women with hair loss.

A young man with an unusual type of scarring hair loss suggests a possible new variant of a known scalp condition.

Topical estrogen helps hair growth in menopausal women with no major side effects.

Combination of minoxidil and finasteride is more effective in increasing hair diameter than minoxidil alone for female-pattern hair loss.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.